Health Catalyst Finalizes Vitalware Sale, Pays Off Debt, and Posts Q2 Upside

summarizeSummary

Health Catalyst closed the Vitalware sale for $147 million, fully repaid its credit facility, and reported Q2 results that beat guidance. Q3 guidance implies a steep sequential revenue decline as the divested unit rolls off.

check_boxKey Events · Earnings and Guidance · HCAT

• Vitalware Divestiture Closed

  Completed sale of Vitalware to Med-Metrix for $147 million in cash on July 31, 2026, subject to customary adjustments.

• Credit Facility Fully Repaid

  Used net proceeds plus cash on hand to repay $159.9 million in principal, $3.2 million prepayment premium, and accrued interest, terminating the credit agreement and releasing all liens.

• Q2 Revenue and EBITDA Beat

  Q2 revenue of $70.5 million exceeded the high end of $68–$70 million guidance; Adjusted EBITDA of $9.9 million beat the midpoint.

• Q3 Guidance Implies Sharp Decline

  Q3 revenue guided to $55–$56 million, down ~21% sequentially, reflecting the loss of Vitalware; Adjusted EBITDA guided to $0–$0.5 million.

auto_awesomeAnalysis · HCAT · Technology

The $147 million Vitalware divestiture closed, and the proceeds—together with cash on hand—were used to fully repay the credit facility, wiping out roughly $19 million in annual interest expense and materially strengthening the balance sheet. Q2 revenue of $70.5 million came in above the high end of guidance, while Adjusted EBITDA of $9.9 million exceeded the midpoint. However, the Q3 revenue guide of $55–$56 million marks a sharp sequential drop as Vitalware's contribution rolls off, and the full-year Adjusted EBITDA target of $18–$18.5 million implies a back-half ramp. Although the debt payoff removes a significant overhang, the revenue reset and persistent net losses keep the outlook cautious.